<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872740</url>
  </required_header>
  <id_info>
    <org_study_id>15-9576</org_study_id>
    <nct_id>NCT02872740</nct_id>
  </id_info>
  <brief_title>Gastric Arterial Embolization for Weight Loss</brief_title>
  <official_title>Gastric Arterial Embolization for Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: Embolization of Gastric Arterial Supply for Weight Loss&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      10 patients&#xD;
&#xD;
      Study Population: Morbidly obese patients who were seen by the bariatric surgery program at&#xD;
      Toronto Western Hospital but are either not interested or not eligible for surgery.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Single center, randomized, prospective, non-blinded pilot study.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      12 months (November 2015 - December 2015).&#xD;
&#xD;
      Agent:&#xD;
&#xD;
      150-250 micron polyvinyl alcohol particles&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To further evaluate the safety of embolization of the left gastric and gastroepiploic&#xD;
      arteries. To determine if either or both will result in significant weight loss and decrease&#xD;
      in waist circumference among obese patients.&#xD;
&#xD;
      Primary objective measure:&#xD;
&#xD;
      The number of adverse events in a 1 year period will be recorded. The weight change from&#xD;
      baseline will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>1 year</time_frame>
    <description>weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>1 year</time_frame>
    <description>serum lipids, hemoglobin A1C, blood pressure, sleep apnea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Embolization of Left Gastric Artery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will have their left gastric artery embolized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Embolization of Gastroepiploic Artery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will have their gastroepiploic artery embolized</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization of Left Gastric Artery</intervention_name>
    <description>Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles</description>
    <arm_group_label>Embolization of Left Gastric Artery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization of Gastroepiploic Artery</intervention_name>
    <description>Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles</description>
    <arm_group_label>Embolization of Gastroepiploic Artery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet standard eligibility criteria for bariatric surgery. BMI of &gt;= 40 -or- BMI of&#xD;
             &gt;=35 with one of the following comorbid conditions: hypertension, type 2 diabetes,&#xD;
             obstructive sleep apnea, coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Basic&#xD;
&#xD;
        Unable to provide informed consent (legally authorized representative is acceptable) Unable&#xD;
        or unwilling to come for follow up appointments Age &lt; 18 or &gt;80 Weight &gt;400 lbs or 180kg&#xD;
        due to weight limits on angiographic tables Moderate or severe allergy to iodinated&#xD;
        contrast media not amenable to premedication as defined by the ACR contrast guidelines&#xD;
        Pregnant, breastfeeding or actively trying to become pregnant in the next year Inability to&#xD;
        lie flat for the duration of the procedure Limited life expectancy &lt; 1 year Patient&#xD;
        enrolled in another interventional study, they will be permitted to enter this study 30&#xD;
        days after reaching the prior studies primary endpoint Arterial anatomy not feasible for&#xD;
        intervention based on investigator assessment&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
        Pre-existing chronic abdominal pain History of inflammatory bowel disease History of&#xD;
        gastroparesis Prior history of gastric surgery, embolization or radiation Prior or current&#xD;
        history of peptic ulcer disease Significant risk factors for peptic ulcer disease including&#xD;
        daily NSAID use, active smoking or active H. Pylori infection Abnormal upper endoscopy&#xD;
        Hepatic Cirrhosis Portal venous hypertension Hepatic Bilirubin &gt; 2.0 mg/dL Albumin &lt; 2.5&#xD;
        g/L&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
        Known aortic pathology such as aneurysm or dissection Peripheral arterial disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
        Renal insufficiency as evidenced by estimated GFR &lt; 60ml/min.1.73m2&#xD;
&#xD;
        Hematologic/Immunologic/Oncologic/Infectious&#xD;
&#xD;
        Acute or chronic infection Active cancer or prior history of cancer &lt;10 years ago&#xD;
        Autoimmune disease requiring immunosuppression Neutrophils &lt; 1.5 x 10^9/L Platelets &lt; 50 x&#xD;
        10^9/L INR &gt;1.7&#xD;
&#xD;
        Psychiatric&#xD;
&#xD;
        Major diagnosed psychiatric comorbidities such a major depressive disorder, schizophrenia,&#xD;
        bipolar disorder that are deemed to likely interfere with follow up History of an eating&#xD;
        disorder such as anorexia or bulimia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Martin Simons</investigator_full_name>
    <investigator_title>BSc, MD, FRCPC, FSIR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

